Parker-Hannifin Corporation (PH) is slated to release third-quarter fiscal 2025 (ended March 2025) results on May 1, before market open.(Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The Zacks Consensus Estimate for revenues is pegged at $5 billion, indicating a decline of 1.5% from the prior-year quarter’s number. The consensus mark for earnings is pinned at $6.73 per share, which has inched up 0.3% in the past 30 days. The figure indicates an increase of 3.4% from the year-ago qu ...

Arthur J. Gallagher & Co. (AJG) is expected to register an improvement in its top and bottom lines when it reports first-quarter 2025 results on May 1, after the closing bell.The Zacks Consensus Estimate for AJG’s first-quarter revenues is pegged at $3.75 billion, indicating 16.4% growth from the year-ago reported figure.The consensus estimate for earnings is pegged at $3.57 per share. The Zacks Consensus Estimate for AJG’s first-quarter earnings has moved up 3.8% in the past 60 days. The estimate suggests ...

Exelon's first-quarter earnings are expected to have continued to benefit from its reduction in volumetric risk, as nearly 78% of its distribution revenues are decoupled. The company's bottom line is expected to have benefited from its rate case activities. New electric and gas rates implemented during the first and previous quarters in EXC's service regions should have contributed positively. The bottom line is expected to have benefited from ongoing energy efficiency programs and rising demand from data c ...

National Fuel Gas Company (NFG) is scheduled to release fiscal second-quarter 2025 results on April 30, after market close. The company delivered an earnings surprise of 5.7% in the last reported quarter. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Let’s discuss the factors that are likely to be reflected in the upcoming quarterly results.Key Factors That May Impact NFG's Q2 ResultsNational Fuel Gas received approval on Dec. 19, 2024, from the New York Public Service Commission to ...

We expect GSK plc (GSK) to surpass expectations when it reports first-quarter 2025 earnings on April 30, before the opening bell. The company’s earnings beat estimates by 11.32% in the last reported quarter.The Zacks Consensus Estimate for sales and earnings is pegged at $9.54 billion and $1.08 per American depositary share (ADS), respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Factors Shaping GSK’s Upcoming ResultsGSK reports financial figures under three segments — S ...

EOG Resources, Inc. (EOG) is set to report first-quarter 2025 results on May 1, after market close.In the last reported quarter, its adjusted earnings of $2.74 per share beat the Zacks Consensus Estimate of $2.55, primarily driven by higher production volumes. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)EOG’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 5.95%. This is depicted in the graph below: Estimat ...

Zacks Rank: ICE carries a Zacks Rank #2 at present. Intercontinental Exchange Inc. (ICE) is expected to register an improvement in its top and bottom lines when it reports first-quarter 2025 results on May 1, before market open. The Zacks Consensus Estimate for ICE's first-quarter revenues is pegged at $2.46 billion, indicating 7.4% growth from the year-ago reported figure. Factors Likely to Shape Q1 Results of ICE Continued strong trends across fixed-income data and analytics and an acceleration in growth ...

PPG Industries Inc. (PPG) is set to release first-quarter 2025 results after the closing bell on April 29. PPG Industries missed the Zacks Consensus Estimate for earnings in two of the trailing four quarters, beat once while delivering in-line results on the other occasion. It delivered a trailing four-quarter negative earnings surprise of around 0.6%, on average. While the company is expected to have benefited from acquisitions and restructuring cost savings in the first quarter, its performance is likely ...

Investors didn't rush to buy Lockheed Martin stock this week. They might want to reconsider.Lockheed Martin (LMT 2.39%) reported earnings on Tuesday, and the crowd went mild.Seriously. Rarely has an earnings beat the size of the one Lockheed reported this week been met with such a gigantic collective shrug of dismissal as this one. Heading into earnings day, Wall Street analysts confidently predicted Lockheed would report a $6.31-per-share profit on $17.8 billion in sales. Instead, Lockheed reported $18 bil ...

Core Viewpoint - Investors are keenly awaiting Exelixis' first-quarter 2025 results, particularly focusing on the performance of its lead drug, Cabometyx, with sales and earnings estimates at $502.8 million and 42 cents per share respectively [1] Group 1: Financial Performance - Exelixis has a history of earnings surprises, beating estimates in three of the last four quarters with an average surprise of 26.87%, including a 7.84% beat in the last reported quarter [1] - The Zacks Consensus Estimate for Cabometyx sales is $434 million, while the model estimate is $457.3 million, indicating strong sales performance [3] - Collaboration revenues have increased due to higher royalty revenues from cabozantinib sales outside the U.S., a trend expected to continue [4] Group 2: Product Developments - Cabometyx is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma, maintaining its status as the leading TKI for RCC [3] - Recent FDA approvals expanded Cabometyx's label for treating adult and pediatric patients with previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET) [5][6] Group 3: Share Repurchase and Financial Strategy - The board has authorized a $500 million stock repurchase program, expected to commence after completing the ongoing $500 million program [7] - Ongoing share repurchases are likely to positively impact the bottom line, although operating expenses may rise due to costs associated with a broader portfolio [7] Group 4: Earnings Prediction - The earnings model predicts a potential earnings beat for Exelixis, supported by a positive Earnings ESP of +7.14% and a Zacks Rank of 3 [8][9] - The Most Accurate Estimate for earnings is 45 cents per share, compared to the consensus estimate of 42 cents [9] Group 5: Stock Performance - Exelixis shares have gained 11.4% year-to-date, contrasting with a 3.7% decline in the industry [12]